S-乙基谷胱甘肽 | 24425-52-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: S-乙基谷胱甘肽
• 英文名称: S-Ethyl glutathione
• 英文别名: (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-ethylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
• CAS: 24425-52-3
• 化学式: C₁₂H₂₁N₃O₆S
• 分子量: 335.381
• InChiKey: HMFDVPSBWOHOAP-YUMQZZPRSA-N

物化性质

• 熔点：
  150-153°C
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、超声处理）、水（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  184
• 氢给体数：
  5
• 氢受体数：
  8

ADMET

代谢

Ethylglutathione 是 1-碘乙烷的已知人体代谢物。

Ethylglutathione is a known human metabolite of 1-iodoethane.

来源:NORMAN Suspect List Exchange

制备方法与用途

S-乙基谷胱甘肽是一种生物化学物质。

反应信息

• 作为产物：
  描述：

  谷胱甘肽 、 氯乙烷 在 rat glutathione transferase 5-5 、 sodium borate buffer 作用下， 反应 0.08h， 生成 S-乙基谷胱甘肽
  参考文献：
  名称：

  Conjugation of Haloalkanes by Bacterial and Mammalian Glutathione Transferases:  Mono- and Vicinal Dihaloethanes

  摘要：

  Glutathione (GSH) transferases are generally involved in the detoxication of xenobiotic chemicals. However, conjugation can also activate compounds and result in DNA modification. Activation of 1,2-dihaloethanes (BrCH2CH2Br, BrCH2CH2Cl, and ClCH2CH2Cl) was investigated using two mammalian theta class GSH transferases (rat GST 5-5 and human GST T1) and a bacterial dichloromethane dehalogenase (DM11). Although the literature suggests that the bacterial dehalogenase does not catalyze reactions with CH3Cl, ClCH2CH2Cl, or CH3CHCl2, we found a higher enzyme efficiency for DM11 than for the mammalian GSH transferases in conjugating CH3Cl, CH3CH2Cl, and CH3CH2Br. Enzymatic rates of activation of 1,2-dihaloethanes were determined in vitro by measuring S,S-ethylene-bis-GSH, the major product trapped by nonenzymatic reaction with the substrate GSH. Salmonella typhimurium TA 1535 systems expressing each of these GSH transferases were used to determine mutagenicity. Rates of formation of S,S-ethylene-bis-GSH by the GSH transferases correlated with the mutagenicity determined in the reversion assays for the three 1,2-dihaloethanes, consistent with the view that half-mustards are the mutagenic products of the GSH transferase reactions. Half-mustards [S-(2-haloethyl)GSH] containing either F, Cl, or Br (as the leaving group) were tested for their abilities to induce revertants in S. typhimurium, and rates of hydrolysis were also determined. GSH transferases do not appear to be involved in the breakdown of the half-mustard intermediates. A halide order (Br > Cl) was observed for both GSH transferase-catalyzed mutagenicity and S,S-ethylene-bis-GSH formation from 1,2-dihaloethanes, with the single exception (both assays) of BrCH2CH2Cl reaction with DM11, which was unexpectedly high. The lack of substrate saturation seen for conjugation of dihalomethanes with GSTs 5-5 and T1 was also observed with the mono- and 1,2-dihaloethanes [Wheeler, J. B., Stourman, N. V., Thier, R., Dommermuth, A., Vuilleumier, S., Rose, J. A., Armstrong, R. N., and Guengerich, F. P. (2001) Chem. Res. Toxicol. 14, 1118-1127], indicative of an inherent difference in the catalytic mechanisms of the bacterial and mammalian GSH transferases.

  DOI：

  10.1021/tx0100183

文献信息

• Chemical Modification of Proteins
  申请人：Bernardes Goncalo

  公开号：US20110144304A1

  公开（公告）日：2011-06-16

  The invention relates to methods for selectively converting a cysteine residue in a peptide or protein to the dehydroalanine (Dha) residue. The method also works on selenocysteine and substituted cysteine and selenocysteine residues, resulting in the Dha residue which may be converted to any natural or unnatural amino acid residue desired without the alteration of the remainder of the peptide or protein. The invention also allows ligation of a desired peptide at any point rather than at a point where there should be a naturally occurring cysteine, thereby allowing native chemical ligation to be used in the synthesis of peptides that do not contain cysteine. The methodology allows for the synthesis of very large peptides.

  本发明涉及一种将肽或蛋白质中的半胱氨酸残基选择性转化为去氢丙氨酸（Dha）残基的方法。该方法也适用于硒半胱氨酸和取代的半胱氨酸和硒半胱氨酸残基，从而产生Dha残基，该残基可以转化为所需的任何天然或非天然氨基酸残基，而不改变肽或蛋白质的其余部分。本发明还允许在任何点上连接所需的肽，而不是在应该存在天然半胱氨酸的点上进行连接，从而允许在合成不含半胱氨酸的肽时使用天然化学连接。该方法允许合成非常大的肽。
• Präparat zur Wirkstoffapplikation in Kleinsttröpfchenform
  申请人：Cevc, Gregor, Prof. Dr.

  公开号：EP0475160A1

  公开（公告）日：1992-03-18

  Die Erfindung betrifft ein Präparat zur Applikation von Wirkstoffen in Form kleinster, insbesondere mit einer membranartigen Hülle aus einer oder wenigen Lagen amphiphiler Moleküle bzw. mit einer amphiphilen Trägersubstanz versehenen Flüssigkeitströpfchen, insbesondere zum Transport des Wirkstoffes in und durch natürliche Barrieren und Konstriktionen wie Häute und dergleichen. Das Präparat weist einen Gehalt einer randaktiven Substanz auf, der bis zu 99 Mol.-% des Gehaltes dieser Substanz entspricht, durch den der Solubilisierungspunkt der Tröpfchen erreicht wird. Das Präparat eignet sich zur nichtinvasiven Verabreichung von Antidiabetica, insbesondere von Insulin. Die Erfindung betrifft außerdem ein Verfahren zur Herstellung solcher Präparate.

  本发明涉及一种以微小液滴形式施用活性物质的制剂，特别是具有一层或几层两亲性分子或两亲性载体物质的膜状包膜，尤其是用于将活性物质输送到或通过皮肤等天然屏障和收缩物。制剂中边缘活性物质的含量最高可达 99 摩尔%，从而达到液滴的溶解点。该制剂适用于非侵入性给药抗糖尿病药物，特别是胰岛素。本发明还涉及生产这种制剂的工艺。
• Water-soluble rapamycin derivatives
  申请人：Zhejiang Hisun Pharmaceutical Co., Ltd.

  公开号：US10442835B2

  公开（公告）日：2019-10-15

  The present invention relates to technical fields of organic chemistry and pharmaceutical chemistry, specifically to water-soluble rapamycin derivatives modified with glutathione. More specifically, the present invention discloses a compound of formula I and the preparation method thereof, wherein R1 and R2 are as defined in the description. The compound of formula I can be used in inducing immunosuppression and in the treatment of diseases such as transplant rejection and solid tumor, etc.

  本发明涉及有机化学和药物化学技术领域，具体涉及用谷胱甘肽修饰的水溶性雷帕霉素衍生物。更具体地说，本发明公开了一种式 I 的化合物及其制备方法，其中 R1 和 R2 如说明中所定义。式 I 的化合物可用于诱导免疫抑制和治疗诸如移植排斥和实体瘤等疾病。
• Treatment of dandruff
  申请人：Unilever Home & Personal Care USA, Division of Conopco, Inc.

  公开号：US20020168327A1

  公开（公告）日：2002-11-14

  Dandruff and symptoms of dandruff can be treated using lipophilic agents or lipid precursor and/or promoters to strengthen the scalp. The lipophilic agents or lipid precursor and/or promoters are preferably used in conjunction with an antifungal agent which has activity against Malassezia spp, particularly Malassezia furfur . Suitable antifungal agents include those conventionally used for the treatment of dandruff including, for example, zinc pyrithrone (ZnPTO), octopirox and azole antifungal agents such as climbazole and ketocanazole. The antifungal agents may be used singularly or as a mixture of one or more antifungal agents.

  头皮屑和头皮屑症状可使用亲脂剂或脂质前体和/或促进剂来治疗，以增强头皮的功效。亲脂剂或脂质前体和/或促进剂最好与具有抗马拉色菌活性的抗真菌剂一起使用，特别是 糠秕马拉色菌 .合适的抗真菌剂包括传统上用于治疗头皮屑的抗真菌剂，例如吡蚜酮锌 (ZnPTO)、辛吡罗和唑类抗真菌剂，如爬山唑和酮康唑。这些抗真菌剂可单独使用，也可作为一种或多种抗真菌剂的混合物使用。
• S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide
  申请人：——

  公开号：US20020187137A1

  公开（公告）日：2002-12-12

  A method of inhibiting the actions of S-nitrosothiols and nitric oxide which often occur in conditions such as septic shock, chronic or acute pain syndromes, uterine hypotonus, or certain gastrointestinal disorders. The method involving inhibiting the cellular binding of S-nitrosothiols to their cellular receptors or the signal transduction that would result. This is accomplished by administering an S-alkylthiol such as S-methyl-L-cysteine or S-ethyl-L-cysteine to a patient as an antagonist of S-nitrosothiol.

  一种抑制 S-亚硝硫醇和一氧化氮作用的方法，这些作用通常发生在脓毒性休克、慢性或急性疼痛综合征、子宫收缩乏力或某些胃肠道疾病等情况中。该方法涉及抑制 S-亚硝硫醇与其细胞受体的细胞结合或由此产生的信号转导。具体方法是向患者施用一种 S-烷基硫醇，如 S-甲基-L-半胱氨酸或 S-乙基-L-半胱氨酸，作为 S-亚硝硫醇的拮抗剂。